AZT Media Release: Chinese Patent Application Granted for Transmucosal Delivery of tocotrienols
Azure Health Technology Limited (AZT), the Company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform which eliminates the use of needles, is pleased to announce that the China National Intellectual Property Administration has issued a Notification to Grant Patent Right for Invention for a patent application titled: ‘Transmucosal delivery of tocotrienol’.
- Azure Health granted IP patent protection in China
- Patent covers Azure’s novel transmucosal delivery of tocotrienol
- Supports Azure’s global commercialisation strategy where patent have been granted in major markets including the US, Europe and Japan and many others
- Treatment and prevention of muscle soreness following exercise is a massive global unmet need
Sydney, Australia 1 October 2020 – Azure Health Technology Limited (AZT), the Company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform which eliminates the use of needles, is pleased to announce that the China National Intellectual Property Administration has issued a Notification to Grant Patent Right for Invention for a patent application titled: ‘Transmucosal delivery of tocotrienol’.
The patent application is directed to transmucosal delivery of tocotrienols for the treatment or prevention of Delayed Onset Muscle Soreness (DOMS), and once granted, will provide patent rights in China until 2033. AZT is preparing to lodge a divisional patent application which will expand the scope of patent coverage in China.
AZT has corresponding patents granted in the US, the European Union, Japan, Australia, New Zealand, Singapore and South Africa as well as a Notice of Allowance issued by the Canadian Patent Office. The grant of this Chinese patent will provide AZT with a growing patent estate spanning major markets which supports its global commercialisation strategy for both its drug development program and nutraceuticals business.
Dr Glenn Tong, the Chief Executive Officer and Managing Director of AZT, said “China is a rapidly emerging market of enormous value to both our pharmaceuticals and nutraceuticals businesses as evidenced by major pharmaceutical and human consumer health companies which have placed a high priority on making an entry into this market. We are very pleased to have secured these patent rights”.
For more information please contact:
Dr Glenn Tong
CEO and Managing Director
Tel: +61 (0) 412 193 350
Mr Warrick Lace
Reach Corporate Pty Ltd
+61 (0) 404 656 408
Ms Catriona Glover
Tel: +61 (0) 402 328 200
About Azure Health Technology Limited
Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: www.azureht.com.au
Azure Health Technology Limited
ABN: 35 111 082 485
Address: Level 45, MLC Centre, 19 Martin Place, Sydney NSW 2000
www.azureht.com.au | Tel: +61 2 8279 8908
This media release was originally published on 1st October 2020 by Azure Health Technology. Reach Markets has permission from AZT to publish it. The views and opinions expressed in this media release are those of the author and do not necessarily reflect the views and opinions of Reach Markets.
Reach Markets have been engaged by AZT to help manage their investor communications.
General Advice Warning
Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG) including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.
Please click here to read our full warning.